CRBU logo

Caribou Biosciences, Inc. Common Stock

CRBU

CRBU: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.

more

Show CRBU Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of CRBU by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by CRBU's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Engineered cascade components and cascade complexes Jan. 17, 2023
  • Patent Title: Engineered nucleic acid-targeting nucleic acids Nov. 22, 2022
  • Patent Title: Humanized bcma antibody and bcma-car-t cells Oct. 18, 2022
  • Patent Title: Methods of use of crispr cpf1 hybrid dna/rna polynucleotides Oct. 04, 2022
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Apr. 26, 2022
  • Patent Title: Humanized bcma antibody and bcma-car-t cells Apr. 12, 2022
  • Patent Title: Crispr hybrid dna/rna polynucleotides and methods of use Feb. 01, 2022
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Jan. 18, 2022
  • Patent Title: Methods for using dna repair for cell engineering Oct. 26, 2021
  • Patent Title: Bcma-car-natural killer (nk) cells and methods related thereto Oct. 12, 2021
  • Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides Sep. 07, 2021
  • Patent Title: Humanized bcma antibody and bcma-car-t cells Jun. 01, 2021
  • Patent Title: Engineered nucleic acid-targeting nucleic acids May. 11, 2021
  • Patent Title: Method of target cleaving using crispr hybrid dna/rna polynucleotides Apr. 27, 2021
  • Patent Title: Modified cascade ribonucleoproteins and uses thereof Mar. 23, 2021
  • Patent Title: Humanized bcma antibody and bcma-car-t cells Feb. 23, 2021
  • Patent Title: Engineered cascade components and cascade complexes Sep. 22, 2020
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Jul. 14, 2020
  • Patent Title: Modified cascade ribonucleoproteins and uses thereof Jul. 14, 2020
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Dec. 10, 2019
  • Patent Title: Engineered cascade components and cascade complexes Oct. 29, 2019
  • Patent Title: Modified cascade ribonucleoproteins and uses thereof Oct. 08, 2019
  • Patent Title: Engineered cascade components and cascade complexes Jun. 25, 2019
  • Patent Title: Engineered cascade components and cascade complexes Mar. 12, 2019
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Feb. 05, 2019
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Nov. 27, 2018
  • Patent Title: Methods of modifying a target nucleic acid with an argonaute Nov. 13, 2018
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Nov. 13, 2018
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Nov. 13, 2018
  • Patent Title: Engineered nucleic acid-targeting nucleic acids Oct. 16, 2018
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Jul. 17, 2018
  • Patent Title: Methods for increasing cas9-mediated engineering efficiency May. 15, 2018
  • Patent Title: Engineered nucleic acid-targeting nucleic acids May. 15, 2018
  • Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides May. 15, 2018
  • Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides May. 15, 2018
  • Patent Title: Cells comprising engineered nucleic-acid targeting nucleic acids May. 01, 2018
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Mar. 06, 2018
  • Patent Title: Methods of modifying a target nucleic acid with an argonaute Feb. 27, 2018
  • Patent Title: Modified cascade ribonucleoproteins and uses thereof Feb. 06, 2018
  • Patent Title: Engineered nucleic acid-targeting nucleic acids Nov. 14, 2017
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Nov. 14, 2017
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Nov. 07, 2017
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Oct. 31, 2017
  • Patent Title: Engineered nucleic acid-targeting nucleic acids Sep. 26, 2017
  • Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides Aug. 29, 2017
  • Patent Title: Methods of using engineered nucleic-acid targeting nucleic acids Aug. 29, 2017
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Aug. 08, 2017
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Jun. 13, 2017
  • Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides Feb. 28, 2017
  • Patent Title: Compostions and methods of nucleic acid-targeting nucleic acids Aug. 09, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CRBU in WallStreetBets Daily Discussion

CRBU News

Recent insights relating to CRBU

CNBC Recommendations

Recent picks made for CRBU stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CRBU

Corporate Flights

Flights by private jets registered to CRBU